Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

As far as B Absssi being low hanging fruit, I tend to disagree. As pointed out by others there is significant competition in that space especially with Dapto soon to lose patent protection implying generic competition. The fact is first-in-class drugs are more expensive to bring to market and may not ultimately be the best-in-class drugs. The incredible pace of scientific research benefits the follow-on drug makers at least to some degree IMO. While the innovator drug is in development, makers of follow-on drugs have the ability to survey the competitive landscape and decide on a project based on its scientific and financial merits. They can also glean information from drugs in development ahead of them, giving them the chance to improve on the first-in-class drug even before it hits the market. These factors and the financial cost of at least two PIII trials required by the FDA combined to limit BP partnership offers thus shifting the cost benefit analysis in favor of concentrating on developing B-OM and B-UP as there is limited competition, if any, and systemic absorption is limited lowering the probability of SAE's. The focus is exactly what Dr. B said it was, economically based.